retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Michael Weintraub, MD on X: "Retatrutide, a (GLP1, GIP, glucagon), just released 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight Hitting the Triple G Spot:

That does not mean the product page should make endpoint claims

This L-glutathione ingredients meets the specification for the Japanese Pharmacopoeia (JP) and the USP monograph (USP).This solution provides 350 mg of phospholipid complex from non-GMO, sunflower oil and lecithin per serving and uses a liposomal delivery system to help with the bioavailability of glutathione Have antioxidant properties* Promote cardiovascular health* Support the immune system and adrenaline synthesis, offering liver support* Suggested Use / Directions: Take 2 capsules daily with water or as directed by your healthcare practitioner

While such reluctance is understandable, it would be a mistake to allow the FDAs disastrous history of weight loss drugs to make us cynical rather than skeptical

A.KassabG

These peptides are not intended for human consumption, medical treatment, veterinary applications, or any use outside controlled research environments

Importantly it gave Mojsov a highly sensitive means to distinguish GLP-1 (7-37) from the larger molecule GLP-1 (1-37) based on the difference in their charges (Mojsov interview